

List of Publications by Citations

Source: <https://exaly.com/author-pdf/7390804/elena-pontarini-publications-by-citations.pdf>
Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

32 papers	828 citations	15 h-index	28 g-index
36 ext. papers	1,101 ext. citations	5.9 avg, IF	3.8 L-index

#	Paper	IF	Citations
32	Human liver-resident CD56(bright)/CD16(neg) NK cells are retained within hepatic sinusoids via the engagement of CCR5 and CXCR6 pathways. <i>Journal of Autoimmunity</i> , 2016 , 66, 40-50	15.5	152
31	Lactate Buildup at the Site of Chronic Inflammation Promotes Disease by Inducing CD4 T Cell Metabolic Rewiring. <i>Cell Metabolism</i> , 2019 , 30, 1055-1074.e8	24.6	122
30	BLyS upregulation in Sjogren's syndrome associated with lymphoproliferative disorders, higher ESSDAI score and B-cell clonal expansion in the salivary glands. <i>Rheumatology</i> , 2013 , 52, 276-81	3.9	109
29	The role of natural killer cells in autoimmune liver disease: a comprehensive review. <i>Journal of Autoimmunity</i> , 2013 , 46, 55-65	15.5	61
28	The 158VV Fcgamma receptor 3A genotype is associated with response to rituximab in rheumatoid arthritis: results of an Italian multicentre study. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 716-21	2.4	42
27	The CC homozygosis of the -174G>C IL-6 polymorphism predicts a lower efficacy of rituximab therapy in rheumatoid arthritis. <i>Autoimmunity Reviews</i> , 2012 , 11, 315-20	13.6	38
26	Treatment with belimumab restores B cell subsets and their expression of B cell activating factor receptor in patients with primary Sjogren's syndrome. <i>Rheumatology</i> , 2015 , 54, 1429-34	3.9	38
25	Unique expansion of IL-21+ Tfh and Tph cells under control of ICOS identifies Sjogren's syndrome with ectopic germinal centres and MALT lymphoma. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 1588-1594	3.9	38
24	Role of oral cyclophosphamide in the treatment of giant cell arteritis. <i>Rheumatology</i> , 2012 , 51, 1677-86	3.9	35
23	Lymphomas complicating primary Sjogren's syndrome: from autoimmunity to lymphoma. <i>Rheumatology</i> , 2019 ,	3.9	25
22	Dopamine inhibits the effector functions of activated NK cells via the upregulation of the D5 receptor. <i>Journal of Immunology</i> , 2014 , 193, 2792-800	5.3	25
21	Current views on the pathogenesis of Sjogren's syndrome. <i>Current Opinion in Rheumatology</i> , 2018 , 30, 215-221	5.3	23
20	Serum levels of anti-CCP antibodies, anti-MCV antibodies and RF IgA in the follow-up of patients with rheumatoid arthritis treated with rituximab. <i>Autoimmunity Highlights</i> , 2010 , 1, 87-94	3.7	21
19	The TTTT B lymphocyte stimulator promoter haplotype is associated with good response to rituximab therapy in seropositive rheumatoid arthritis resistant to tumor necrosis factor blockers. <i>Arthritis and Rheumatism</i> , 2013 , 65, 88-97		19
18	CXCL13 as biomarker for histological involvement in Sjogren's syndrome. <i>Rheumatology</i> , 2020 , 59, 165-170	3.9	17
17	Expression variability and function of the RET gene in adult peripheral blood mononuclear cells. <i>Journal of Cellular Physiology</i> , 2014 , 229, 2027-37	7	9
16	Impaired Interleukin-27-Mediated Control of CD4+ T Cell Function Impact on Ectopic Lymphoid Structure Formation in Patients With Sjogren's Syndrome. <i>Arthritis and Rheumatology</i> , 2020 , 72, 1559-1570	8.5	7

15	One year in review 2020: pathogenesis of primary Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2020 , 38 Suppl 126, 3-9	2.2	7
14	Composite of Relevant Endpoints for Sjögren's Syndrome (CRESS): development and validation of a novel outcome measure. <i>Lancet Rheumatology</i> , 2021 , 3, e553-e562	14.2	6
13	B cell depletion with rituximab in the treatment of primary Sjögren's syndrome: what have we learnt?. <i>Clinical and Experimental Rheumatology</i> , 2019 , 37 Suppl 118, 217-224	2.2	6
12	Blocking T cell co-stimulation in primary Sjögren's syndrome: rationale, clinical efficacy and modulation of peripheral and salivary gland biomarkers. <i>Clinical and Experimental Rheumatology</i> , 2020 , 38 Suppl 126, 222-227	2.2	6
11	Tertiary Lymphoid Organs in Rheumatoid Arthritis. <i>Current Topics in Microbiology and Immunology</i> , 2020 , 426, 119-141	3.3	5
10	Chlamydophila psittaci subclinical infection in chronic polyarthritis. <i>Clinical and Experimental Rheumatology</i> , 2011 , 29, 977-82	2.2	5
9	The use of digital image analysis in the histological assessment of Sjögren's syndrome salivary glands improves inter-rater agreement and facilitates multicentre data harmonisation. <i>Clinical and Experimental Rheumatology</i> , 2020 , 38 Suppl 126, 180-188	2.2	4
8	NK cell recruitment in salivary glands provides early viral control but is dispensable for tertiary lymphoid structure formation. <i>Journal of Leukocyte Biology</i> , 2019 , 105, 589-602	6.5	3
7	NKp30 Receptor Upregulation in Salivary Glands of Sjögren's Syndrome Characterizes Ectopic Lymphoid Structures and Is Restricted by Rituximab Treatment. <i>Frontiers in Immunology</i> , 2021 , 12, 706737	8.4	2
6	A clinical and histopathological analysis of the anti-centromere antibody positive subset of primary Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2018 , 36 Suppl 112, 145-149	2.2	2
5	Cellular and molecular diversity in Sjögren's syndrome salivary glands: Towards a better definition of disease subsets. <i>Seminars in Immunology</i> , 2021 , 101547	10.7	1
4	Advanced imaging for quantification of abnormalities in the salivary glands of patients with primary Sjögren's syndrome. <i>Rheumatology</i> , 2021 , 60, 2396-2408	3.9	0
3	Stepwise changes in the murine salivary gland immune response during virally-induced ectopic lymphoid structure formation. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39, 39-48	2.2	0
2	Immunofibroblasts regulate LTβ expression in tertiary lymphoid structures in a pathway dependent on ICOS/ICOSL interaction.. <i>Communications Biology</i> , 2022 , 5, 413	6.7	0
1	Development and performance of the Clinical Trials ESSDAI (ClinTrialsESSDAI), consisting of frequently active clinical domains, in two randomised controlled trials in primary Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39, 100-106	2.2	